Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Global Subcutaneous Immunoglobulin Market Analysis & Forecast 2024-2034, By Product, Application, End-user and Region | ||
| By: PR Newswire Association LLC. - 22 Mar 2024 | Back to overview list |
|
|
DUBLIN, March 21, 2024 /PRNewswire/ -- The "Global Subcutaneous Immunoglobulin Market Analysis & Forecast to 2024-2034: Market By Product; By Application; By End-user; and By Region" report has been added to ResearchAndMarkets.com's offering.  The global subcutaneous immunoglobulin market size was estimated to be USD 10.35 billion in 2023 and is expected to reach at USD 27.33 billion by 2034 with a CAGR of 9.23% during the forecast period 2024-2034. Rising utilization of subcutaneous immunoglobulin for primary immunodeficiency disorders, growing elderly population, increasing prevalence of immunodeficiency conditions such as HIV, uptake of both organic & inorganic strategies, surge in research & development initiatives, a higher frequency of new drug product introductions, and an escalation in approvals for innovative subcutaneous immunoglobulin products are some of the key factors boosting the market growth. An escalation in approvals for innovative subcutaneous immunoglobulin products is predicted boost the market growth during the forecast period. The subcutaneous administration of immunoglobulin offers more consistent serum immunoglobulin levels and a reduced occurrence of systemic adverse effects compared to the intravenous route. This approach enhances the patient's quality of life by enabling self-administration or administration by a caregiver in the home setting. For instance, in April 2023, CSL Behring, a leading biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) has given approval for a prefilled syringe of 50mL/10gm for Hizentra (Subcutaneous Human Immunoglobulin 20% Liquid). By product, IgG was the highest revenue-grossing segment in the global subcutaneous immunoglobulin market in 2023 owing to the growing trend in the acceptance of immunoglobulins, coupled with an upward trajectory in the regulatory approvals of novel products in this category. Additionally, IgA is predicted to grow at the fastest CAGR during the forecast period owing to the rising occurrence of product launches and a surge in research and development endeavors. By application, secondary immunodeficiency diseases was the highest revenue-grossing segment in the global subcutaneous immunoglobulin market in 2023 owing to the increasing prevalence of AIDS, immune system-related cancers such as leukemia, immune-complex diseases such as viral hepatitis, and rising number of approvals for drug candidates targeting secondary immunodeficiency. Additionally, primary immunodeficiency diseases is predicted to grow at the fastest CAGR during the forecast period owing to the rising use of interventions to boost the immune system and an increasing emphasis on creating innovative treatment alternatives for primary immunodeficiency diseases are becoming more prominent. By end-user, hospitals was the highest revenue-grossing segment in the global subcutaneous immunoglobulin market in 2023 owing to the growth of healthcare facilities catering to the requirements of both developed and emerging nations has led to a rise in the number of patients seeking hospital care and an increase in the approval of groundbreaking drugs. For instance, in September 2023, Takeda announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] for individuals aged 2 years and older who have been diagnosed with agammaglobulinemia or hypogammaglobulinemia. These conditions are characterized by significantly low or absent antibody levels, increasing the susceptibility to severe recurring infections related to both primary immunodeficiency (PID) and secondary immunodeficiency (SID). Additionally, home care settings is predicted to grow at the fastest CAGR during the forecast period owing to the subcutaneous route poses minimal risk of severe systemic reactions, increase in patients choosing home administration of subcutaneous immunoglobulin (SCIG) due to its convenient method, straightforward technique, ready availability of programmable pumps, and rising demand among elderly patients. North America region is anticipated for the highest revenue share during the forecast period owing to the high incidence of immunodeficiency diseases, a rising elderly population, well-established healthcare infrastructure, increasing occurrences of breast cancer and genital cancers, a growing need for immunoglobulin, and numerous notable advancements are taking place in the region. For instance, in January 2023, KORU Medical Systems, Inc., a prominent medical technology firm specializing in drug delivery systems, revealed a collaborative development agreement with a pharmaceutical manufacturer specializing in subcutaneous immunoglobulin therapy (SCIg). The objective is to create and pursue regulatory approval for the Freedom Infusion System, featuring a prefilled syringe for SCIg. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of neurological, immunological, & diverse disorders, growing advancements in antibody therapy, a surge in public health awareness, and an escalation in approvals by regulatory authorities. Company Profiles
Report Segmentation: By Product
By Application
By End-user
By Region
For more information about this report visit https://www.researchandmarkets.com/r/y4u9z About ResearchAndMarkets.com Media Contact: Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets 
|
||
|
|
||
 | Back to overview list | |
View original content: